ATE421094T1 - Screeningverfahren für kombinationen von biologischen verbindungen - Google Patents

Screeningverfahren für kombinationen von biologischen verbindungen

Info

Publication number
ATE421094T1
ATE421094T1 AT04790957T AT04790957T ATE421094T1 AT E421094 T1 ATE421094 T1 AT E421094T1 AT 04790957 T AT04790957 T AT 04790957T AT 04790957 T AT04790957 T AT 04790957T AT E421094 T1 ATE421094 T1 AT E421094T1
Authority
AT
Austria
Prior art keywords
compounds
cancer
combinations
screening process
biological compounds
Prior art date
Application number
AT04790957T
Other languages
English (en)
Inventor
Mark Nesbit
Alfred Spada
Wei He
Michael Myers
Original Assignee
Centelion
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion, Aventis Pharma Inc filed Critical Centelion
Application granted granted Critical
Publication of ATE421094T1 publication Critical patent/ATE421094T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT04790957T 2003-10-07 2004-10-07 Screeningverfahren für kombinationen von biologischen verbindungen ATE421094T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50885903P 2003-10-07 2003-10-07

Publications (1)

Publication Number Publication Date
ATE421094T1 true ATE421094T1 (de) 2009-01-15

Family

ID=34465087

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04790957T ATE421094T1 (de) 2003-10-07 2004-10-07 Screeningverfahren für kombinationen von biologischen verbindungen

Country Status (6)

Country Link
EP (1) EP1687642B1 (de)
AT (1) ATE421094T1 (de)
CA (1) CA2549579A1 (de)
DE (1) DE602004019135D1 (de)
DK (1) DK1687642T3 (de)
WO (1) WO2005038465A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128740A2 (en) * 2005-06-02 2006-12-07 Centelion Anti-vascular methods and therapies employing lysyl oxidase inhibitors
US8900619B2 (en) * 2006-08-24 2014-12-02 Boston Scientific Scimed, Inc. Medical devices for the release of therapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092468T3 (es) * 1988-01-22 1996-12-01 Zymogenetics Inc Metodos para producir analogos de receptores secretados.
DE69222637T2 (de) * 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US6180632B1 (en) * 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
WO2002072578A2 (en) * 2001-03-08 2002-09-19 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases

Also Published As

Publication number Publication date
WO2005038465A2 (en) 2005-04-28
DK1687642T3 (da) 2009-05-11
EP1687642A2 (de) 2006-08-09
EP1687642B1 (de) 2009-01-14
DE602004019135D1 (de) 2009-03-05
CA2549579A1 (en) 2005-04-28
WO2005038465A3 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
MY148985A (en) 2-aminopyridine analogs as glucokinase activators
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
EP1481077A4 (de) Mitotische kinesin-hemmer
DE60231439D1 (de) Mitotische kinesinhemmer
EP1765362A4 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
DE60329990D1 (de) Mitotische kinesin-hemmer
DE60329756D1 (de) Mitotische kinesin-hemmer
CY1108927T1 (el) Αναστολεις μιτωτικης κινεσινης
ATE502941T1 (de) Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
ATE521608T1 (de) Glucokinaseaktivatoren
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
ATE343575T1 (de) Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ATE266031T1 (de) Verfahren und verbindungen zur behandlung proliferativer erkrankungen
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
ATE424208T1 (de) Proteinkinaseinhibitoren
TW200740808A (en) Inhibiteurs de proteines kinases
EP1507778A4 (de) Polzcyclische carbonsäureamide mit antitumorwirkung
DE602004019135D1 (de) Screeningverfahren für Kombinationen von biologischen Verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties